-
The first patient enrolled in the clinical trial of the innovative drug MDM2-p53 antagonist for the treatment of DDLPS in China
Time of Update: 2023-02-03
On January 5, 2023, Boehringer Ingelheim announced that its innovative drug MDM2-p53 antagonist BI 907828 for the first-line treatment of dedifferentiated liposarcoma (DDLPS) Phase II. /III. clinical
-
InnoCare will present the latest research data of Gunagratinib in the treatment of cholangiocarcinoma at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium
Time of Update: 2023-02-03
Poster display : The highly selective irreversible FGFR inhibitor Gunagratinib in previously treated patients with locally advanced or metastatic FGFR gene abnormalities with cholangiocarcinoma: a phase IIa dose expansion study Summary code: 572 Sub-venue: Poster venue B: Pancreatic cancer, small bowel cancer and hepatobiliary cancer When: January 20, 12:00 PM - 1:30 PM US time : Professor Guo Ye ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
-
Yuyue Medical responded to the question of the price increase of oximeter: the discount was canceled due to the increase in costs
Time of Update: 2023-02-03
Yuyue Medical responded that the company's production and operation are legal and compliant, and there is no price increase in oximeter products at present, and discounts and discounts have been canceled due to rising costs.
-
InnoCare announces that Tafasitamab in combination with lenalidomide has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma in Hong Kong, China
Time of Update: 2023-02-03
On December 28, 2022, InnoCare (SSE: 688428; Hong Kong Stock Exchange code: 09969) today announced that tafasitamab in combination with lenalidomide has been approved by the Hong Kong Department of Health for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation.
-
Kangzhi Pharmaceutical responded to the problem of montmorillonite bulk production capacity: overtime production to ensure supply
Time of Update: 2023-02-03
Kangzhi Pharmaceutical responded to investors on the interactive platform on the 3rd that the company has produced and sold montmorillonite, and the product has passed the consistency evaluation of the quality and efficacy of generic drugs in early 2021.
-
CanSino disclosed the results of a recent sequential strengthening clinical study of the new crown mRNA epidemic
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];The novel coronavirus mRNA epidemic seedling CS-2034 (hereinafter referred to as "CS-2034"), jointly developed by CanSino Biologics Co.
js?cdnversion='+~(-new Date()/36e5)];The novel coronavirus mRNA epidemic seedling CS-2034 (hereinafter referred to as "CS-2034"), jointly developed by CanSino Biologics Co.
-
Renfu Pharmaceutical became powerful, grabbing Hengrui's exclusive injection that soared 137%.
Time of Update: 2023-02-03
Figure 3: Clinical trial of esketamine hydrochloride injection of Yichang Renfu PharmaceuticalSource: Minainet new version of the database Yichang Renfu Pharmaceutical submitted a Class 3 generic marketing application for esketamine hydrochloride injection for the first time in 2020, and was finally approved for clinical trials, and its confirmatory clinical trial was completed in June this year, and the marketing application is now submitted again, which shows that the company attaches great importance to this product.
-
Alphyn Biologics reports positive results from the first cohort of a Phase 2a trial for the treatment of mild to moderate atopic dermatitis
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Alphyn Biologics, a clinical-stage dermatology company that develops the first multi-target therapeutic, announced January 5 positive results in its Phase 2a clinical trial for the treatment of mild to moderate atopic dermatitis (AD) topical AB-101a.
-
Oculis completed Phase 1 patient recruitment for Phase 3 clinical DIAMOND
Time of Update: 2023-02-03
Boyer, MD, Clinical Professor of Ophthalmology at the Keck School of Medicine of Southern California and principal investigator of the DIAMOND clinical trial, said: "The way topical drugs are treated will bring important advantages, including early intervention and treatment accessibility, convenience, and non-invasiveness.
-
First Drug Holdings disclosed that SY-5007, a selective RET inhibitor, conducts pivotal clinical trials
Time of Update: 2023-02-02
js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co.
js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co.
js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co.
js?cdnversion='+~(-new Date()/36e5)];Recently, First Drug Holdings (Beijing) Co.
-
Double-blind treatment period completed The first phase 3 clinical trial of parathyroid hormone replacement therapy in China will be analyzed as the primary endpoint
Time of Update: 2023-02-02
VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine-related therapeutics, announced on January 6 that its Phase 3 clinical trial (PaTHway China trial), an innovative drug in research, has completed a double-blind treatment period on January 4, 2023, and will soon undergo primary endpoint analysis 。 Paroperteitriparatide is administered once daily to restore 24-hour physiological levels of parathyroid hormone (PTH [1-34]) in adult patients with hypoparathyroidism (hypoparathyroidism, HP).
-
Jacobio completed the first patient dosing of the Aurora A inhibitor JAB-2485 in the United States
Time of Update: 2023-02-02
HK) independently developed the world's first innovative drug Aurora (aurora kinase A) inhibitor JAB-2485 phase I/IIa clinical study completed the first dosing of patients with advanced solid tumors in the United States.
-
CStone Pharmaceuticals announced that the registrational clinical study of Zhijimei (R) (sugemalimab injection) for the first-line treatment of esophageal squamous cell carcinoma has reached the primary endpoint and intends to submit a marketing application for a new indication
Time of Update: 2023-02-02
CStone Pharmaceuticals (HKEx: 2616), a leading biopharmaceutical company focused on the development, development and commercialization of innovative immunotherapies and precision therapies for oncolo
-
Tianyan Pharmaceutical announced its ADG126Ib/II anti-CTLA-4 antibody Phase 126Ib/II clinical dose escalation interim data
Time of Update: 2023-02-02
js?cdnversion='+~(-new Date()/36e5)];On January 9, the company announced clinical trial data on the combination of its masked anti-CTLA-4 safe antibody SAFEbody ADG126 and anti-PD-1 therapy in patients with advanced/metastatic solid tumors.
-
Sinovac: The new crown treatment drug SHEN26 has completed the enrollment of phase II subjects
Time of Update: 2023-02-02
According to the announcement, at this stage, Sinovac Pharmaceutical is conducting a "randomized, double-blind, placebo-controlled phase II clinical study of SHEN26 capsules for the treatment of mild and common novel coronavirus infected patients", and the main endpoint indicator is the change in SARS-CoV-2 viral RNA level (RT-PCR test) relative to the baseline.
-
Pulse Biopharma announced that the ADC drug PRO1184, targeting FRα, has completed the dosing of the first subject
Time of Update: 2023-02-02
js?cdnversion='+~(-new Date()/36e5)];Pufang, a clinical-stage biopharmaceutical company focused on the development of next-generation macromolecule-targeted anti-cancer drugs, announced that its ADC drug PRO1184 (clinical trial number NCT05579366) has completed the first subject administration of the Phase I clinical trial, and the clinical trial application for the ADC drug PRO1160 has been approved by the US Food and Drug Administration (FDA).
-
Innovent announces that mazdutide (IBI362) has completed the first dose of mazdutide (IBI362) in a Phase III clinical study (DREAMS-1) in subjects with type 2 diabetes in China
Time of Update: 2023-02-01
, announced: glucagon-like peptide-1 receptor (GLP-1R) / glucagon receptor, GCGR) dual agonist mazdutide (R&D code: IBI362) was administered in a multicenter, randomized, double-blind, placebo-controlled phase III clinical study (DREAMS-1) in subjects with type 2 diabetes in China.
-
Insilico Releases Positive Top-Line Data for Phase I Clinical Trials of INS018_055 Antifibrotic Drugs
Time of Update: 2023-02-01
"Insilico, a clinical-stage biotechnology company powered by end-to-end artificial intelligence (AI), announces that its idiopathic pulmonary fibrosis (IPF) drug candidate INS018_055 positive top-line data in a Phase I clinical trial in New Zealand with good performance in terms of safety, tolerability, and pharmacokinetics (PK).
-
Qilu Pharmaceutical's ophthalmic medication pipeline has ushered in a new member!
Time of Update: 2023-02-01
News on January 12, Qilu Pharmaceutical issued an announcement that the company's brimonidine timolol eye drops (including multi-dose and single-dose two packaging specifications) were approved for marketing by the National Medical Products Administration and deemed to have passed the consistency evaluation, of which the single-dose packaging is exclusively listed in China.
-
Bio4T2 announces CAR-T vaccination for the first patient
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression present in multiple types of solid tumors.
js?cdnversion='+~(-new Date()/36e5)];Bio4t2 inoculated the first patient with T cells containing chimeric antigen receptors (CARs), targeting BT-001 antigen overexpression present in multiple types of solid tumors.
